Abstract
Human Respiratory Syncytial Virus (hRSV) is a major cause of acute respiratory disease most common in newborns, children and the elderly, responsible for complications such as Bronchiolitis and Pneumonia. Currently, there is only one treatment for pediatric patients at high risk, with Palivizumab and data on vaccine development are not satisfactory. Among the proteins encoded by the virus…